Sarcoidosis is one of the leading causes of inflammatory eye disease. Ocular sarcoidosis can involve any part of the eye and its adnexal tissues, and may cause uveitis, episcleritis/scleritis, eyelid abnormalities, conjunctival granuloma, optic neuropathy, lacrimal gland enlargement and orbital inflammation. Glaucoma and cataract can be complications from inflammation itself or adverse effects from therapy. Ophthalmic manifestations can be isolated, or associated with other organ involvement. Patients with ocular sarcoidosis can present with a wide range of clinical presentations and severity. Multi-disciplinary approaches are required to achieve the best treatment outcomes for both ocular and systemic manifestations
PurposeSarcoidosis is a chronic idiopathic granulomatous inflammatory disease that can affect many m...
Sarcoidosis is treated, whenn ecessary, primarily with corticosteroids. Ocular disease oftenrespon d...
Purpose: To describe the ocular manifestations in a cohort of patients with systemic sarcoidosis (SS...
Sarcoidosis is a chronic inflammatory disease of unknown etiology that affects many systemic organs,...
Ocular involvement in sarcoidosis occurs in ∼40% and the eye is the presenting organ in roughly 20%....
Ocular manifestation of sarcoidosis occurs in up to 60% of patients with confirmed systemic sarcoido...
The data of national and foreign literature review and personal observations data analysis in patien...
Ocular sarcoidosis leads to inflammation of the eye, manifesting as uveitis, scleritis and conjuncti...
Sarcoidosis is an inflammatory disease that involves the eyes in 10-55% of cases, sometimes without ...
Sarcoidosis is an idiopathic systemic granulomatous disease. It commonly affects the skin, lungs, ki...
Sarcoidosis is a systemic disease that has ocular manifestations. For many patients there is a long ...
Sarcoidosis can involve any part of the eye and may be the major manifestation of the disease, even ...
Ocular involvement is present in up to 79% of sarcoid patients. Uveitis is the main ocular manifesta...
Aims To establish expert recommendations for the management of ocular sarcoidosis (OS). Methods A qu...
Glaucoma is a major cause of permanent visual loss in patients with sarcoid uveitis.In this case gla...
PurposeSarcoidosis is a chronic idiopathic granulomatous inflammatory disease that can affect many m...
Sarcoidosis is treated, whenn ecessary, primarily with corticosteroids. Ocular disease oftenrespon d...
Purpose: To describe the ocular manifestations in a cohort of patients with systemic sarcoidosis (SS...
Sarcoidosis is a chronic inflammatory disease of unknown etiology that affects many systemic organs,...
Ocular involvement in sarcoidosis occurs in ∼40% and the eye is the presenting organ in roughly 20%....
Ocular manifestation of sarcoidosis occurs in up to 60% of patients with confirmed systemic sarcoido...
The data of national and foreign literature review and personal observations data analysis in patien...
Ocular sarcoidosis leads to inflammation of the eye, manifesting as uveitis, scleritis and conjuncti...
Sarcoidosis is an inflammatory disease that involves the eyes in 10-55% of cases, sometimes without ...
Sarcoidosis is an idiopathic systemic granulomatous disease. It commonly affects the skin, lungs, ki...
Sarcoidosis is a systemic disease that has ocular manifestations. For many patients there is a long ...
Sarcoidosis can involve any part of the eye and may be the major manifestation of the disease, even ...
Ocular involvement is present in up to 79% of sarcoid patients. Uveitis is the main ocular manifesta...
Aims To establish expert recommendations for the management of ocular sarcoidosis (OS). Methods A qu...
Glaucoma is a major cause of permanent visual loss in patients with sarcoid uveitis.In this case gla...
PurposeSarcoidosis is a chronic idiopathic granulomatous inflammatory disease that can affect many m...
Sarcoidosis is treated, whenn ecessary, primarily with corticosteroids. Ocular disease oftenrespon d...
Purpose: To describe the ocular manifestations in a cohort of patients with systemic sarcoidosis (SS...